• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Strategies for the improvement of thrombolytic agents.

作者信息

Lijnen H R, Collen D

出版信息

Thromb Haemost. 1991 Jul 12;66(1):88-110.

PMID:1926054
Abstract
摘要

相似文献

1
Strategies for the improvement of thrombolytic agents.
Thromb Haemost. 1991 Jul 12;66(1):88-110.
2
[Biochemical, pharmacologic and clinical properties of new thrombolytic agents].新型溶栓剂的生化、药理及临床特性
Internist (Berl). 1996 Jun;37(6):552-66.
3
Fibrinolytic agents: mechanisms of activity and pharmacology.纤维蛋白溶解剂：作用机制与药理学
Thromb Haemost. 1995 Jul;74(1):387-90.
4
[Plasminogen activators as thrombolytic agents in myocardial infarction].[纤溶酶原激活剂作为心肌梗死的溶栓药物]
Rev Hosp Clin Fac Med Sao Paulo. 1989 Nov-Dec;44(6):288-94.
5
Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.组织型纤溶酶原激活剂（t-PA）和单链尿激酶型纤溶酶原激活剂（scu-PA）：纤维蛋白特异性溶栓治疗的潜力。
Prog Hemost Thromb. 1986;8:1-18.
6
Approach to the patient with venous thromboembolism. Treatment with thrombolytic agents.静脉血栓栓塞症患者的诊疗方法。溶栓药物治疗。
Hematol Oncol Clin North Am. 1992 Oct;6(5):1141-59.
7
[Development of the high effective thrombolytic agents with molecular biological technique].[利用分子生物学技术开发高效溶栓剂]
Zhonghua Nei Ke Za Zhi. 1993 Jan;32(1):11-3.
8
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂（K2tu-PA：CGP 42935）的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.
9
Towards the development of improved thrombolytic agents.
Br J Haematol. 1991 Mar;77(3):261-6. doi: 10.1111/j.1365-2141.1991.tb08568.x.
10
[Arterial thrombolysis. Review and future prospects].[动脉溶栓。综述与未来展望]
J Mal Vasc. 1988;13(4):307-16.

引用本文的文献

1
Development and Testing of Thrombolytics in Stroke.溶栓药物在中风治疗中的研发与测试。
J Stroke. 2021 Jan;23(1):12-36. doi: 10.5853/jos.2020.03349. Epub 2021 Jan 31.
2
The evolution of recombinant thrombolytics: Current status and future directions.重组溶栓剂的演变：现状与未来方向。
Bioengineered. 2017 Jul 4;8(4):331-358. doi: 10.1080/21655979.2016.1229718. Epub 2016 Oct 3.
3
High-level expression of a novel recombinant human plasminogen activator (rhPA) in the milk of transgenic rabbits and its thrombolytic bioactivity in vitro.
新型重组人纤溶酶原激活剂（rhPA）在转基因兔乳汁中的高效表达及其体外溶栓生物活性
Mol Biol Rep. 2016 Aug;43(8):775-83. doi: 10.1007/s11033-016-4020-0. Epub 2016 May 26.
4
Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli.通过大肠杆菌中的自诱导实现活性重组人组织型纤溶酶原激活剂的可溶性表达、纯化及特性鉴定
BMC Biotechnol. 2015 Mar 1;15:13. doi: 10.1186/s12896-015-0127-y.
5
Modular design, expression and characterization of novel bifunctional mutants of fibrolase with combined platelet aggregation-inhibition and fibrinolytic activity.纤维酶新型双功能突变体的模块化设计、表达和表征，具有血小板聚集抑制和纤溶活性的双重功能。
Protein J. 2011 Apr;30(4):247-52. doi: 10.1007/s10930-011-9326-0.
6
C-terminal truncation of alpha-COP affects functioning of secretory organelles and calcium homeostasis in Hansenula polymorpha.α-COP的C末端截短影响多形汉逊酵母中分泌细胞器的功能和钙稳态。
Eukaryot Cell. 2004 Feb;3(1):52-60. doi: 10.1128/EC.3.1.52-60.2004.
7
Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.替奈普酶在急性心肌梗死溶栓治疗中的药代动力学和药效学
Clin Pharmacokinet. 2002;41(15):1229-45. doi: 10.2165/00003088-200241150-00001.
8
Aggregation and retention of human urokinase type plasminogen activator in the yeast endoplasmic reticulum.人尿激酶型纤溶酶原激活剂在酵母内质网中的聚集与滞留
BMC Mol Biol. 2002 Oct 7;3:15. doi: 10.1186/1471-2199-3-15.
9
Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.使用基于肝素/鱼精蛋白的药物递送系统合成并表征作为前药的带正电荷的组织型纤溶酶原激活剂。
AAPS PharmSci. 2000;2(1):E7. doi: 10.1208/ps020107.
10
Molecular basis of thrombolytic therapy.溶栓治疗的分子基础。
J Nucl Cardiol. 2000 Jul-Aug;7(4):373-81. doi: 10.1067/mnc.2000.108608.